The impact of conisation on pregnancy outcome

Aim: The objective of present study was to investigate whether conisation is associated with adverse pregnancy outcomes in Flanders, Belgium. Therefore a retrospective cohort study was conducted at the Antwerp University Hospital. Materials and Methods: The study was approved by the Ethical Committee and based on a questionnaire as well as on medical records. Confounders, like smoking, alcohol use, drug use, chronic illness, and gynaecological disorders during pregnancy were all taken into account. A multiple logistic regression was performed for an association between adverse pregnancy outcomes and confounders. Results: The study showed that there was association between conisation, low birth weight, and caesarean section. After conisation there was a significantly higher risk of 3.275 on a low birth weight. The risk of a caesarean section after conisation was tripled. A gynaecological disorder during the pregnancy had a significantly higher risk of delivering a child with a low birth weight and a higher risk of a caesarean section. Smoking and a chronic illness gave a significant higher risk of caesarean section. Discussion: Conisation is easy to perform and highly effective in the prevention of cervical cancer. Conisation has a high morbidity, as it is associated with severe adverse pregnancy outcome. A conisation should therefore only be performed on a true indication; otherwise it will be the victim of its own success.

HPV; Conisation; Preterm delivery; Adverse pregnancy outcomes; Vaccination; Cancer; CIN; HSIL; LSIL; Morbidity; Caesarean; Low-birth weight.

[1] de Sanjosé S., Diaz M., Castellsagué X., Clifford G., Bruni L., Muñoz N., et al.: "Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis”. Lancet Infect. Dis., 2007, 7, 453.

[2] Arbyn M., Benoy I., Simoens C., Bogers J., Beutels P., Depuydt C.: “Prevaccination distribution of human papillomavirus types in women attending at cervical cancer screening in Belgium”. Cancer Epidemiol. Biomarkers Prev., 2009, 18, 321.

[3] Tjalma W.A., Fiander A., Reich O., Powell N., Nowakowski A.M., Kirschner B., HERACLES/SCALE Study Group, et al.: “Differences in human papillomavirus type distribution in high-grade cervical intraepithelial neoplasia and invasive cervical cancer in Europe. Int. J. Cancer, 2013, 132, 854.

[4] Seoud M., Tjalma W.A., Ronsse V.: “Cervical adenocarcinoma: moving towards better prevention”. Vaccine, 2011, 29, 9148.

[5] Holl K., Nowakowski A.M., Powell N., McCluggage W.G., Pirog E.C., Collas De Souza S., et al.: “Human papillomavirus prevalence and type-distribution in cervical glandular neoplasias: Results from a European multinational epidemiological study”. Int. J. Cancer, 2015 Jun 20. doi: 10.1002/ijc.29651. [Epub ahead of print].

[6] Tjalma W.A.A., Trinh X.B., Rosenlund M., Makar A.P., Kridelka F., Rosillon D., et al.: “A cross-sectional, multicentre, epidemiologicalstudy on human papillomavirus (HPV) type distribution in adult women diagnosed with invasive cervical cancer in Belgium”. Facts Views Vis. Obgyn., 2015, 7, 101.

[7] Tjalma W.A.: “The ideal cervical cancer screening recommendation for Belgium, an industrialized country in Europe”. Eur. J. Gynaecol. Oncol., 2014, 35, 211.

[8] Jordan J., Arbyn M., Martin-Hirsch P., Schenck U., Baldauf J.J., Da Silva D., et al.: “European guidelines for quality assurance in cervical cancer screening: recommendations for clinical management of abnormal cervical cytology, part 1”. Cytopathology, 2008, 19, 342.

[9] Jordan J., Martin- Hirsch P., Arbyn M., Schenck U., Baldauf J.J., DaSilva D., et al.: “European guidelines for clinical management of abnormal cervical cytology, part 2”. Cytopathology, 2009, 20, 5.

[10] Tjalma W.A., Arbyn M., Paavonen J., van Waes T.R., Bogers J.J.: “Prophylactic human papillomavirus vaccines: the beginning of the end of cervical cancer”. Int. J. Gynecol. Cancer, 2004, 14, 751.

[11] Saslow D., Solomon D., Lawson H.W., Killackey M., Kulasingam S.L., Cain J., et al.: “American Cancer Society, American Society forColposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer”. Am. J. Clin. Pathol., 2012, 137, 516.

[12] Bjerre P., Silfverdal L., Dillner L., Hagmar B., Edvardsson H., Dillner J., Andersson-Ellström A.: “A randomized trial of basing treatment on human papillomavirus and/or cytology results in low-grade cervical lesion triage”. Am. J. Obstet. Gynecol., 2008, 199, 24.

[13] Kyrgiou M., Koliopoulos G., Martin-Hirsch P., Kehoe S., Flannelly G., Mitrou S., et al.: “Management of minor cervical cytological abnormalities: a systematic review and a meta-analysis of the literature”. Cancer Treat. Rev., 2007;33:514.

[14] Alonso I., Torné A., Puig-Tintoré L.M., Esteve R., Quinto L., Garcia S., et al.: “High-risk cervical epithelial neoplasia grade 1 treated by loop electrosurgical excision: follow-up and value of HPV testing”. Am. J. Obstet. Gynecol., 2007, 197, 359.

[15] Tjalma WA.: “There are two prophylactic human papillomavirus vaccines against cancer, and they are different”. J. Clin. Oncol., 2015, 33, 964.

[16] Struyf F., Colau B., Wheeler C.M., Naud P., Garland S., Quint W., et al.: “HPV PATRICIA Study Group. Post hoc analysis of the PATRICIA randomized trial of the efficacy of human papillomavirus type 16 (HPV-16)/HPV-18 AS04-adjuvanted vaccine against incident and persistent infection with nonvaccine oncogenic HPV types using an alternative multiplex type-specific PCR assay for HPV DNA”. Clin. Vaccine Immunol., 2015, 22, 235.

[17] Szarewski A., Skinner S.R., Garland S.M., Romanowski B., Schwarz T.F., Apter D., et al.: “Efficacy of the HPV-16/18 AS04- adjuvanted vaccine against low-risk HPV types (PATRICIA randomizedtrial): an unexpected observation”. J. Infect. Dis., 2013, 208, 1391.

[18] Mathevet P., Chemali E., Roy M., Dargent D.: “Long-term outcome of a randomized study comparing three techniques of conization: cold knife, laser, and LEEP”. Eur. J. Obstet. Gynecol. Reprod. Biol., 2003;106:214.

[19] Janthanaphan M., Wootipoom V., Tangsinmunkong K., Liabsuetrakul T.: “Comparison of success rate and complications of contour- loop excision of the transformation zone (C-LETZ) with cold knife conization (CKC) in high grade lesion (HGL) from colposcopic impression”. J. Med. Assoc. Thai., 2009, 92, 1573.

[20] Grubisić G., Vukosavić-Cimić B., Kraljević Z., Pirkić A., Grbavac I., Bolanca I.: “Cytologic follow-up in patients with CIN treated by LLETZ, Cold knife Conization and Semm's cold coagulation”. Coll. Antropol., 2010, 34, 13.

[21] Phadnis S.V., Atilade A., Young M.P., Evans H., Walker P.G.: “The volume perspective: a comparison of two excisional treatments for cervical intraepithelial neoplasia (laser versus LLETZ)”. BJOG, 2010, 117, 615.

[22] Prendiville W.: “Large loop excision of the transformation zone”. Clin. Obstet. Gynecol., 1995;38:622.

[23] Aleman J.M., Ariën F., Jacquemyn Y., Tjalma W.: “The consequencesof conisation on pregnancy outcome: a literature o verview (De gevolgen van conisatie op zwangerschapsuitkomsten: een literatuuroverzicht)”. Tijdschrift voor geneeskunde, 2012, 68, 801.

[24] Goldenberg R.L., Culhane J.F., Iams J.D., Romero R.: “Epidemiology and causes of preterm birth”. Lancet, 2008, 371, 75.

[25] Iams J.D., Romero R., Culhane J.F., Goldenberg R.L.: “Primary, secondary, and tertiary interventions to reduce the morbidity and mortality of preterm birth”. Lancet, 2008, 371, 164.

[26] Samson S.L., Bentley J.R., Fahey T.J., McKay D.J., Gill G.H.: “The effect of loop electrosurgical excision procedure on future pregnancy outcome”. Obstet. Gynecol., 2005, 105, 325.

[27] Crane J.M.: “Pregnancy outcome after loop electrosurgical excision procedure: a systematic review”. Obstet. Gynecol., 2003;102:1058.

[28] Kyrgiou M., Koliopoulos G., Martin-Hirsch P., Arbyn M., Prendiville W., Paraskevaidis E.: “Obstetric outcomes after conservative treatment for intraepithelial or early invasive cervical lesions: systematic review and meta-analysis”. Lancet, 2006, 367, 489.

[29] Werner C.L., Lo J.Y., Heffernan T., Griffith W.F., McIntire D.D., Leveno K.J.: “Loop electrosurgical excision procedure and risk of preterm birth”. Obstet. Gynecol., 2010, 115, 605.

[30] Jakobsson M., Gissler M., Paavonen J., Tapper A.M.: “Loop electrosurgical excision procedure and the risk for preterm birth”. Obstet. Gynecol., 2009, 114, 504.

[31] Sadler L., Saftlas A., Wang W., Exeter M., Whittaker J., McCowan L.: “Treatment for cervical intraepithelial neoplasia and risk of preterm delivery”. JAMA, 2004, 291, 2100.

[32] Tjalma W.A., Depuydt C.E.: “Cervical atypical glandular cells and false negative HPV testing: a dramatic reality of the wrong test at the right place”. Eur. J. Gynaecol. Oncol., 2014, 35,117.

[33] Tjalma W.A, Depuydt C.E.: “Cervical cancer screening: which HPV test should be used--L1 or E6/E7?”. Eur. J. Obstet. Gynecol. Reprod., Biol. 2013, 170, 45.

[34] D'Hauwers K.W., Gadet P.F., Donders A.R., Tjalma W.A.: “Impact of medical education on knowledge and attitudes regarding the human papilloma virus and vaccination: comparison before and 6 years after the introduction of the vaccines”. Vaccine, 2013, 31, 5843.